We’re honored to announce that Novartis was named among Forbes' list of America’s Best Employers for Diversity 2024. DEI is a business imperative for us, as part of our strategy on the path to reimagine medicine for all. This recognition is a testament to our people who are committed to creating solutions for our patients, customers, communities and each other, through inclusive values and behaviors. View the full list and read more about the methodology behind this ranking here: https://lnkd.in/gb3dRS3E #ReimaginingMedicineTogether
Novartis US
Pharmaceutical Manufacturing
East Hanover, New Jersey 80,864 followers
Transforming people’s lives by reimagining medicine.
About us
At Novartis US, our mission is to reimagine medicine and discover new ways to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach nearly 800 million people globally and we are finding innovative ways to provide solutions to address the evolving needs of patients. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Over 41% of global Novartis R&D expenditure ($3.9 billion) was invested in the US in 2019. Our US presence is comprised of nearly 15,000 employees, with campuses across the country including in East Hanover, NJ, Cambridge, MA, and Indianapolis, IN. See our community guidelines: http://bit.ly/2JnT2CP
- Website
-
https://www.novartis.us/
External link for Novartis US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- East Hanover, New Jersey
- Founded
- 1996
- Specialties
- Research, Innovation, Quality, Sustainability, Innovative Medicines, Generic Medicines and Biosimilars, Unique Portfolio Focuses & Broad Healthcare Portfolio, Cell & Gene Therapy, and Data & Digital
Updates
-
Our Chief Customer Engagement Officer US, Desmond Creary has been recognized in Savoy Magazine's esteemed 2024 Most Influential Executives in Corporate America list. This well-deserved recognition highlights Desmond's exceptional leadership and dedication in reimagining medicine beyond innovative science, focusing on understanding patient and customer needs. His commitment to supporting our customers with solutions that go beyond breakthrough medicines truly puts them at the center of all we do. Congratulations, Des, on this remarkable feat acknowledged by Savoy! #ReimaginingMedicine #Savoy https://lnkd.in/gRHH-Xqc
-
-
The journey of everyone touched by a neurological condition is different, but together we can better understand these conditions and strive to make meaningful differences for people living with MS. In Neuroscience, we have been committed to addressing patient needs and tackling some of the most complex conditions, like Multiple Sclerosis and Spinal Muscular Atrophy, through research, innovation, partnerships, and community engagement. We’re thrilled to be attending and presenting at #AAN2024, where groundbreaking conversations around the future of neurological treatments and therapies are taking place. Learn more about our 80-year commitment to tackling neurological conditions here: https://lnkd.in/gZju223M #MS #SMA #AANAM
-
-
Cardiovascular disease affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined. It is time to change that. Novartis has been advancing the scientific understanding and treatment of cardiovascular disease for more than four decades. Through early intervention, pioneering science and technological innovation, we are addressing factors that increase the risk of heart attacks and strokes, improving the function of damaged hearts and easing the burden of care for patients. This past weekend we had the pleasure of attending and presenting at #ACC24. We are so inspired by the groundbreaking science and advancements in the field of cardiology. Together we will help more people with cardiovascular disease live longer and healthier lives.
-
-
Today marks an exciting chapter for #radioligandtherapy (RLT) as Indiana state officials, and professional and patient groups, ZERO Prostate Cancer, Veterans Prostate Cancer Awareness, Prostate Health Education Network, and Society of Nuclear Medicine and Molecular Imaging (SNMMI) joined us at the opening ceremony of our new state-of-the-art RLT manufacturing facility in Indianapolis. The centrally located Indiana facility marks our second to open in the US and serves as our largest and most advanced RLT facility to date. We are committed to further expanding our global manufacturing network in RLT and increasing access to our medicines for patients. RLT is changing the way cancer is treated, and Novartis is proud to be leading the way.
-
-
A better future in rare #KidneyDisease begins with a greater understanding of these complex diseases—including IgA nephropathy (#IgAN) and C3 glomerulopathy (#C3G)—and their significant impact on patients’ daily lives. Through innovation, education and meaningful partnerships, we’re focused on breaking down healthcare barriers and advancing care for people living with these rare kidney diseases. With #NationalKidneyMonth coming to a close, we reaffirm our ongoing commitment to the kidney disease community – to ultimately help improve patient lives. #KidneyMonth #RareDisease
-
What would healthcare be like if it were truly patient-centered? Which technologies, tools and partnerships would make it possible? At the STAT Breakthrough Summit East 2024, we joined fellow healthcare industry leaders to discuss these critical topics. As part of this year’s theme “Focusing on patients – for real” Reshema Kemps-Polanco and Tina Deignan shared how they keep patients at the heart of our work at Novartis; the key is to make decisions as if patients were in the room. US healthcare is becoming more complex and sophisticated — we know more today than ever before. However, as we grow in our understanding of science, the industry must work together and continue to find new and innovative ways to help patients get the medicines they need. And that means keeping the patient voice central to our efforts. Novartis is committed to elevating the patient experience by eliminating non-medical barriers to medicine, and the summits conversations show that we’re in good company. #STATBreakthrough
-
-
While elevated Lp(a) impacts about one in five Americans, it is relatively unknown. We are a proud supporter of the American Heart Association and its efforts to raise much needed awareness for Lp(a), a genetically determined condition that increases cardiovascular disease risk.
“’You just had a heart attack,’ were not the words I expected to hear as a 14-year-old girl when I woke from my hospital bed.” Ceirra Zeiger was a freshman in high school when she learned she had undiagnosed congenital heart defect as well as a blood clot in her coronary artery. The blood clot was caused by elevated Lp(a), a genetic independent risk factor for heart disease. Read her story in her own words: http://spr.ly/6049ZMyk9. The Lp(a) Discovery Project is supported by Novartis US.
-
-
We are proud to support Family Heart Foundation in its crucial effort to raise awareness about elevated Lp(a), a relatively unknown genetically determined condition that increases cardiovascular disease risk. #KnowLpa
The 7 Questions from the #KnowLpa Social Answered by the Family Heart Foundation
-
Approximately 37 million adults in the US are estimated to have chronic kidney disease – including IgA nephropathy (IgAN) and C3 glomerulopathy (C3G) – but surprisingly, most are undiagnosed. We’re honored to support this year’s annual National Kidney Foundation #KidneyWalk and share in NKF’s ongoing commitment to collectively raise much-needed awareness of #KidneyDisease. #NationalKidneyMonth
We are proud to share that Novartis US is supporting this year’s National #KidneyWalk. Their commitment to kidney health aligns with our mission to make a meaningful impact on the lives of millions affected by kidney disease.
The National Kidney Foundation’s 2024 Annual Kidney Walk Returns
kidney.org